HCC: Key topics discussed at ASCO GI & EASL 2022

December 06, 2023 00:13:11
HCC: Key topics discussed at ASCO GI & EASL 2022
COR2ED - Oncology Medical Conversation
HCC: Key topics discussed at ASCO GI & EASL 2022

Dec 06 2023 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode

December 06, 2023 00:21:28
Episode Cover

Upper GI cancer: Update from ESMO 2022 - Part 2

This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022.  Dr Sam Klempner (Massachusetts General Hospital, Boston, USA) and...

Listen

Episode

December 06, 2023 00:28:03
Episode Cover

Endometrial carcinoma: Systemic therapies. Part 2 - The nurses' perspective

Join Lead Nurse Andreia Fernandes and Clinical Nurse Specialist Jo Pearson as they explain how to help patients navigate the side effects of systemic...

Listen

Episode

April 28, 2025 00:18:36
Episode Cover

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment...

Listen